| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) |
Gene disruption
|
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 27241521
|
| MR4 number |
|
| top of page |
| Parent parasite used to introduce the genetic modification |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone |
Not applicable
|
| Other information parent line | |
| top of page |
| The mutant parasite was generated by |
| Name PI/Researcher | Kumar H; Frischknecht F |
| Name Group/Department | Integrative Parasitology |
| Name Institute | Center for Infectious Diseases, Heidelberg University Medical School |
| City | Heidelberg |
| Country | Germany |
| top of page |
| Name of the mutant parasite |
| RMgm number | RMgm-1448 |
| Principal name | LISP2(–) |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page |
| Phenotype |
| Asexual blood stage | Not different from wild type |
| Gametocyte/Gamete | Not different from wild type |
| Fertilization and ookinete | Not different from wild type |
| Oocyst | Not different from wild type |
| Sporozoite | Not different from wild type |
| Liver stage | Normal numbers of sporozoites are formed that are infective to cultured hepatocytes. Parasites arrest during development in hepatocytes after a period of growth. In most parasites no merozoites are formed as shown by the low level of MSP1 expression. After intravenous injection of sporozoites, 1 out of 60 mice developed a blood stage infection |
| Additional remarks phenotype | Mutant/mutation
The mutant lacks expression of LISP2
Protein (function)
PBANKA_100300 encodes a 2172 amino acid protein with a large repeat region of approximately 1000 amino acids. This region is composed of several repeat motifs, particularly 12 copies of a 56-amino acid motif. Analyses of the amino acid sequence with various structure analysis tools indicates that it has an N-terminal signal sequence but no other motifs for membrane association such as transmembrane domains or a GPI-anchor motif, suggesting that the encoded product has the structure of a secreted protein. It contains a predicted Plasmodium 6-cysteine motif. Several studies analysing expression of this protein in P. berghei (see 'Additional mutants') provide evidence for specific expression in liver stages. The protein has been named LISP2 and sequestrin.
Phenotype
Normal numbers of sporozoites are formed that are infective to cultured hepatocytes. Parasites arrest during development in hepatocytes after a period of growth. In most parasites no merozoites are formed as shown by the low level of MSP1 expression. After intravenous injection of sporozoites, 1 out of 60 mice developed a blood stage infection (see also below).
Additional information
The mutant described here show a stronger growth-arrested phenotype in comparison to earlier described mutants lacking expression of LISP2 (see RMgm-799, RMgm-930, RMgm-931), possibly due to expression of the N-terminal region of the lisp2 gene in the latter mutants. Evidence is presented that expression of a small part of the N-terminal region of lisp2 in parasites lacking lisp2 results in a reduced growth arrest in the liver.
Other mutants
See the link PBANKA_1003000 for other related mutants |
*RMgm-1448
